[PDF] Top 20 El tiempo en La muerte de Artemio Cruz

... (67%) patients in the AA treatment arm and 435 (80%) in the P arm received subsequent treatment with one or more agents approved for mCRPC at the discretion of the investigator ... See full document

... The treatment was in continuous 28-d cycles [20]. Patients were stratified by Eastern Cooperative Oncology Group performance status (ECOG PS) score (0 vs ...agent. Patients had the first recorded ... See full document

... to subsequent HT [20 – 22]. In a retrospective study of 436 patients with CRPC treated with secondary HT, the median duration of secondary HT treatment was longer for patients who re- ceived ... See full document

... of AA in mCRPC patients from an unselected pa- tient population in a non-trial ...all AA-treated patients in all public oncology centers during a defined period serves to provide a representa- ... See full document

... docetaxel treatment [18], which led to the phenomenon being referred to as “PSA flare,” indicating a PSA elevation with initiation of an LHRH ...with AA treatment [19, ...such patients showed ... See full document

... for metastatic castration-resistant prostate cancer (mCRPC) has rapidly evolved in recent years with many new agents demonstrating a benefit in overall survival ...is abiraterone ... See full document

... the COU- AA-301 trial in post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone ...of ... See full document

... 1 – Overall survival Kaplan-Meier estimates in COU-AA-301 patients with prior endocrine therapy. 450[r] ... See full document

... Abstract: Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, ... See full document

... Kaplan-Meier analysis was used to estimate ...univariable analysis were selected for testing in multivariable ...the COU-301 and COU-302 trials were used for the postchemotherapy and ... See full document

... and AA, in other words, the existence of an overlapping resistance mecha- ...and AA is the AR-signaling pathway, however these differ in their mechanisms of activity, with enzalutamide inhibiting AR ... See full document

... of patients with progressive, castration- resistant prostate cancer (CRPC) with abiraterone in combination with prednisone leads to an increase in progression-free and overall ... See full document

... enzalutamide for the treatment of mCRPC, and now also used for earlier indications. When looking at the chemical structures of the class of nonsteroidal antiandrogens, there is similarity within all of these ... See full document

... each treatment cycle to prevent emesis. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 and hematological (leukocytes ≥3000/mm 3 ; hemoglobin ≥10 g/dl;and ... See full document

... For castration-resistant cancer cells, it has already been described that ADT increases PSMA ex- pression ...of patients scheduled for PSMA-PET/CT suffered from ... See full document

... Financial disclosures: David Lorente certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript ... See full document

... identify patients with mutations in the exon 8 of AR, we sequenced cfDNA from 15 patients’ plasma at a sin- gle time ...15 patients analyzed were found to have at least one SNV (Additional file  ... See full document

... mCRPC patients treated with abiraterone acetate plus prednisone (AA-P), and explored the possibility that a few clinically available variables could be used to identify subsets of ... See full document

... mCRPC patients treated with first-line AA-P can be divided into groups with significantly different risks of experiencing radiographic progression based on a few clinically available ...example, ... See full document

... in patients with progressive ...for treatment of men with mCRPC, and the importance of using patient-reported symptoms, radio- graphic changes, and changes in other known prognostic biomarkers to determine ... See full document